

## Instructions for Authors 2017

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O'Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2017** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

[www.cgp.iarjournals.org](http://www.cgp.iarjournals.org)

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iarjournals.org](http://www.iarjournals.org)

## A Selection of Recent Articles

Differential Expression of Wisp1 (Ccn4) and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. M.S. CHAHAL, H.T. KU, Z. ZHANG, C.M. LEGASPI, A. LUO, M.M. HOPKINS, K.E. MEIER (*Spokane, WA; Duarte, CA, USA*)

Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (*Basel, Switzerland*)

EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6 Expressing MDA-MB-231 Cells. C. JOHNSON, B. SEGOVIA, R.P. KANDPAL (*Pomona, CA, USA*)

Phospho-Network Analysis Identifies and Quantifies Hepatitis C Virus (HCV)-induced Hepatocellular Carcinoma (HCC) Proteins Regulating Viral Mediated Tumor Growth. N.T. LU, N.M. LIU, J.Q. VU, D. PATEL, W. COHN, J. CAPRI, M. ZIEGLER, N. PATEL, A. TRAMONTANO, R. WILLIAMS, J. COX, J. WHITELEGGE, S.W. FRENCH (*Los Angeles, CA; Boston, MA, USA; London, UK*)

The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (*Basel, Switzerland*)

Association of BIM Deletion Polymorphism and BIM- $\gamma$  RNA Expression in NSCLC with EGFR Mutation. K. ISOBE, A. KAKIMOTO, T. MIKAMI, K. KABURAKI, H. KOBAYASHI, T. YOSHIZAWA, T. MAKINO, H. OTSUKA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, N. TOCHIGI, A. IYODA, S. HOMMA (*Tokyo, Japan*)

High Throughput Screening of Nutraceuticals for Evidence of Human Histone Deacetylase Inhibition and Analysis of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed Extract (*Vitis vinifera*) in HeLa cells. E.A. MAZZIO, K.F.A. SOLIMAN (*Tallahassee, FL, USA*)

A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. J. LU, M.G. BURNETT, M. SHPAK (*Austin, TX; Cambridge, MA, USA*)

The Impact of HRNPM and SLC1A5 in Pathogenesis and Prognosis in Epithelial Ovarian Cancer. K. BJERSAND, T. SEIDAL, I. SUNDSTRÖM POROMAA, H. ÅKERUD, I. SKIRNISDOTTIR (*Uppsala; Halmstad, Sweden*)

Characterization of Heparan Sulfate Proteoglycan-positive Recycling Endosomes Isolated from Glioma Cells. K.A. PODYMA-INOUE, T. MORIWAKI, A.R. RAJAPAKSHE, K. TERASAWA, M. HARA-YOKOYAMA (*Tokyo, Japan*)

Overexpression of HPV16 E6\* Alters  $\beta$ -Integrin and Mitochondrial Dysfunction Pathways in Cervical Cancer Cells. W. EVANS, M. FILIPPOVA, V. FILIPPOV, S. BASHKIROVA, G. ZHANG, M.E. REEVES, P. DUERKSEN-HUGHES (*Loma Linda, CA, USA*)

Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). Y. YOSHIDA, M. NAITO, T. YAMADA, N. AISU, D. KOJIMA, T. MERA, T. TANAKA, K. NAITO, K. YASUMOTO, T. KAMIGAKI, S. GOTOH, S. KODAMA, Y. YAMASHITA, S. HASEGAWA ( <i>Fukuoka; Tokyo, Japan</i> ) .....	3941
Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study. R. TAKIMOTO, T. KAMIGAKI, S. OKADA, E. MATSUDA, H. IBE, E. OGUMA, K. NAITOH, K. MAKITA, S. GOTO ( <i>Tokyo, Japan</i> ) .....	3947
Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer. K. MIYATA, F. YOTSUMOTO, S. FUKAGAWA, C. KIYOSHIMA, N.S. OUK, D. URUSHIYAMA, T. ITO, T. KATSUDA, M. KURAKAZU, R. ARAKI, A. SANUI, D. MIYAHARA, M. MURATA, K. SHIROTA, H. YAGI, T. TAKONO, K. KATO, N. YAEGASHI, K. AKAZAWA, M. KUROKI, S. YASUNAGA, S. MIYAMOTO ( <i>Fukuoka; Sendai; Niigata, Japan</i> ) .....	3955
Perineural Invasion Is a Prognostic Factor and Treatment Indicator in Patients with Rectal Cancer Undergoing Curative Surgery: 2000-2011 Data from a Single-center Study. T. KINUGASA, T. MIZOBE, S. SHIRAIWA, Y. AKAGI, K. SHIROUZU ( <i>Kurume, Japan</i> ) .....	3961
Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management. H. KOBAYASHI, M. HAMASAKI, T. MORISHITA, T. INOUE, K. NABESHIMA ( <i>Fukuoka, Japan</i> ).....	3969
Laparoscopically Removed Streak Gonad Revealed Gonadoblastoma in Frasier Syndrome. K. HASHIMOTO, Y. HORIBE, J. EZAKI, T. KANNO, N. TAKAHASHI, Y. AKIZAWA, H. MATSUI, T. YAMAMOTO, N. SHIBATA ( <i>Tokyo, Japan</i> ) .....	3975
Errata.....	3981

Interactive Analysis of TX-1123 with Cyclo-oxygenase: Design of COX2 Selective TX Analogs. K. OHKURA, Y. TATEMATSU, Y. KAWAGUCHI, Y. UTO, H. HORI ( <i>Suzuka; Choshi; Tokushima, Japan</i> ).....	3849
An Alpha-kinase 2 Gene Variant Disrupts Filamentous Actin Localization in the Surface Cells of Colorectal Cancer Spheroids. K. NISHI, H. LUO, K. NAKABAYASHI, K. DOI, S. ISHIKURA, Y. IWAIHARA, Y. YOSHIDA, K. TANISAWA, T. ARAI, S. MORI, M. SAWABE, M. MURAMATSU, M. TANAKA, T. SAKATA, S. SHIRASAWA, T. TSUNODA ( <i>Fukuoka; Tokyo, Japan</i> ).....	3855
Frequency of Myeloid-derived Suppressor Cells in the Peripheral Blood Reflects the Status of Tumor Recurrence. T. TANAKA, M. FUJITA, H. HASEGAWA, A. ARIMOTO, M. NISHI, E. FUKUOKA, Y. SUGITA, T. MATSUDA, Y. SUMI, S. SUZUKI, Y. KAKEJI, K. YAMASHITA ( <i>Kobe; Osaka, Japan</i> ).....	3863
Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma. T. OKUDA, T. TASAKI, S. NAKATA, K. YAMASHITA, H. YOSHIOKA, S. IZUMOTO, A. KATO, M. FUJITA ( <i>Osaka; Kyoto; Kobe, Japan</i> ).....	3871
Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase. I. SHIBA, R. KOUZAKI, H. YAMADA, Y. ENDO, T. TAKINO, H. SATO, K. KITAZATO, T. KAGEJI, S. NAGAHIRO, Y. UTO ( <i>Tokushima; Kanazawa, Japan</i> ).....	3877
Discordance of <i>MCM7</i> mRNA and its Intronic MicroRNA Levels Under Hypoxia. H. KONDO, Y. SHIMONO, J. MUKOHYAMA, Y. TANAKA, N. SHIBUYA, H. MINAMI, Y. KAKEJI, A. SUZUKI ( <i>Kobe, Japan</i> ).....	3885
Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy. S. FUKAGAWA, F. YOTSUMOTO, T. ODAWARA, S. MANABE, T. ISHIKAWA, S. YASUNAGA, S. MIYAMOTO ( <i>Fukuoka; Kagawa, Japan</i> ).....	3891
Measurement of the Phagocytic Activity of Human Peripheral Blood Using a Highly Sensitive Fluorometric Detection Device Without Hemolysis. R. ZHANG, H. INAGAWA, M. TAKAHASHI, H. KAWANISHI, K. KAZUMURA, H. TSUCHIYA, N. MORISHITA, Y. KOBAYASHI, T. MASAKI, H. KOBARA, G.-I. SOMA ( <i>Kagawa; Niigata; Hamamatsu, Japan</i> ).....	3897
Expression of <i>N</i> -Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer. T. KURITA, T.N. THI, C. KOI, M. MURAKAMI, S. KAGAMI, H. IZUMI, T. HACHISUGA ( <i>Kitakyushu, Japan</i> ).....	3905
Expression of Polypeptide <i>N</i> -Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma. M. MURAKAMI, S. KAGAMI, T.T. NGUYEN, C. KOI, T. KURITA, T. HACHISUGA ( <i>Kitakyushu, Japan</i> ).....	3911
Lipopolysaccharides Derived from <i>Pantoea agglomerans</i> Can Promote the Phagocytic Activity of Amyloid $\beta$ in Mouse Microglial Cells. Y. KOBAYASHI, H. INAGAWA, C. KOHCHI, K. OKAZAKI, R. ZHANG, H. KOBARA, T. MASAKI, G.-I. SOMA ( <i>Kagawa; Niigata, Japan</i> ).....	3917
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated $\alpha\beta$ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. Y. KANEMURA, M. SUMIDA, Y. OKITA, E. YOSHIOKA, A. YAMAMOTO, D. KANEMATSU, Y. HANDA, H. FUKUSUMI, Y. INAZAWA, A. TAKADA, M. NONAKA, S. NAKAJIMA, K. MORI, S. GOTO, T. KAMIGAKI, T. SHOFUDA, S. MORIUCHI, M. YAMASAKI ( <i>Osaka; Hirakata; Nishinomiya; Amagasaki; Tokyo; Izumiotsu; Takatsuki, Japan</i> ).....	3921
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated $\alpha\beta$ T-cells. F. ISHII, Y. YOSHIDA, Y. YAMAUCHI, N. AISU, D. KOJIMA, T. MERA, D. KATO, T. TANAKA, K. NAITO, K. YASUMOTO, T. KAMIGAKI, S. GOTO, Y. HAMADA, S. NIMURA, S. KODAMA, S. HASEGAWA ( <i>Fukuoka; Tokyo, Japan</i> ).....	3933

Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. C. MESCHER, C. DING, T. DEFOR, S. KONETY, A. BLAES ( <i>Minneapolis, MN, USA</i> ).....	3751
The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection. V. MADEKIVI, P. BOSTRÖM, R. AALTONEN, T. VAHLBERG, E. SALMINEN ( <i>Turku, Finland</i> ) .....	3757
Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection. N. HARADA, T. YOSHIKAZUMI, Y.-I. YAMASHITA, Y. SOEJIMA, T. IKEGAMI, N. HARIMOTO, S. ITOH, Y. MAEHARA ( <i>Fukuoka; Kumamoto, Japan</i> ).....	3763
Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). A. WEIN, J. SIEBLER, K. WOLFF, N. OSTERMEIER, D. BUSSE, A. HAGEL, F. KOCH, K. MERX, M.F. NEURATH, R.-D. HOFHEINZ ( <i>Erlangen-Nuremberg; Mannheim, Germany</i> ) .....	3771
Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations. M. NAKAO, H. MURAMATSU, Y. KAGAWA, Y. SUZUKI, Y. SAKAI, R. KUROKAWA, K. FUJITA, H. SATO ( <i>Yatomi, Japan</i> ).....	3781
Neck Dissection and Thoracoscopic Esophagectomy in Esophageal Cancer with Aberrant Subclavian Artery. H. KITAGAWA, T. NAMIKAWA, K. HANAZAKI ( <i>Nankoku, Japan</i> ).....	3787
Hepatitis B Reactivation in a Patient Receiving Chemotherapy for Breast Cancer: A Case Report. M. REMO, I. ABRAHAM, V. KANKANALA, W. CHACRA, O.C. DANCIU ( <i>Chicago, IL, USA</i> ) .....	3791
KLF9 Is a Prognostic Indicator in Human Pancreatic Ductal Adenocarcinoma. Z. MAO, X. FAN, J. ZHANG, X. WANG, X. MA, C.W. MICHALSKI, Y. ZHANG ( <i>Zhenjiang, PR China; Heidelberg, Germany</i> ) .....	3795
Prognostic Importance of Vitamins A, E and Retinol-binding Protein 4 in Renal Cell Carcinoma Patients. R. SOBOTKA, O. ČAPOUN, M. KALOUSOVÁ, T. HANUŠ, T. ZIMA, M. KOŠTÍŘOVÁ, V. SOUKUP ( <i>Prague, Czech Republic</i> ) .....	3801
Correlation Between Minimum Apparent Diffusion Coefficient (ADC <sub>min</sub> ) and Tumor Cellularity: A Meta-analysis. A. SUROV, H.J. MEYER, A. WIENKE ( <i>Leipzig; Halle, Germany</i> ).....	3807
Factors Influencing Disease Progression in Patients with Head and Neck Melanoma. U. USLU, G. SCHULER, H. BREUNINGER ( <i>Erlangen; Tübingen, Germany</i> ) .....	3811
PROCEEDINGS OF THE 20th ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 10 December, 2016 ( <i>Fukuoka, Japan</i> ) .....	3817-3980
Clinicopathological and Corresponding Genetic Features of Colorectal Signet Ring Cell Carcinoma ( <i>Review</i> ). K. TAJIRI, T. SUDOU, F. FUJITA, T. HISAKA, T. KINUGASA, Y. AKAGI ( <i>Fukuoka, Japan</i> ).....	3817
HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of <i>EGFR</i> <sup>T790M</sup> . F. YOTSUMOTO, S. FUKAGAWA, K. MIYATA, S.O. NAM, T. KATSUDA, D. MIYAHARA, T. ODAWARA, S. MANABE, T. ISHIKAWA, S. YASUNAGA, S. MIYAMOTO ( <i>Fukuoka; Kagawa, Japan</i> ).....	3825
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant <i>KRAS</i> . K. NISHI, H. LUO, S. ISHIKURA, K. DOI, Y. IWAIHARA, L. WILLS, G.S. BAILLIE, T. SAKATA, S. SHIRASAWA, T. TSUNODA ( <i>Fukuoka, Japan; Glasgow, Scotland, UK</i> ).....	3833
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of <i>Jak2</i> V617F-induced Murine Myeloproliferative Neoplasm. T. YAMAJI, K. SHIDE, T. KAMEDA, M. SEKINE, A. KAMIUNTEN, T. HIDAKA, Y. KUBUKI, H. SHIMODA, H. ABE, T. MIIKE, H. IWAKIRI, Y. TAHARA, M. SUETA, S. YAMAMOTO, S. HASUIKE, K. NAGATA, K. SHIMODA ( <i>Miyazaki, Japan</i> ).....	3841

Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries. A.I. MARIAMPILLAI, J.P. DELA CRUZ, J. SUH, A. SIVAPIRAGASAM, K. NEVINS, A.A. HINDENBURG ( <i>Mineola; Syracuse; New York, NY; Paramus, NJ, USA</i> ) .....	3649
Self-Efficacy for Coping with Cancer Enhances the Effect of Reiki Treatments During the Pre-Surgery Phase of Breast Cancer Patients. A. CHIRICO, G. D'AIUTO, A. PENON, L. MALLIA, M. DE LAURENTIIS, F. LUCIDI, G. BOTTI, A. GIORDANO ( <i>Rome; Naples; Siena, Italy; Philadelphia, PA, USA</i> ) .....	3657
Evaluation of Bone Turnover/Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Y. MIYAZAWA, S. TAKAHIRO, S. YOSHITAKA, M. NOMURA, H. KOIKE, H. MATSUI, Y. SHIBATA, K. ITO, K. SUZUKI ( <i>Maebashi, Japan</i> ) .....	3667
Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer. A. KUMAR, M.L. TORRES, W.A. CLIBY, K.R. KALLI, G. BOGANI, G. ALETTI, C.C. NITSCHMANN, F. MULTINU, A.L. WEAVER, M.S. BLOCK, A. MARIANI ( <i>Rochester, MN, USA; Milan, Italy</i> ).....	3673
Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade. C. GREENE, E.K. NAKAKURA, A.H. KO ( <i>San Francisco, CA, USA</i> ).....	3679
Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes. A. KAITO, T. KINOSHITA, M. TOKUNAGA, H. SUNAGAWA, M. WATANABE, S. SUGITA, A. TONOUCHE, R. SATO, I. ABE, T. AKIMOTO ( <i>Kashiwa; Tokyo, Japan</i> ).....	3685
Clinicopathological Characteristics of Metaplastic Papillary Tumor of the Fallopian Tube. M. JANG, J.-Y. SUNG, J.-Y. KIM, H.-S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	3693
Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer. H. SATAKE, M. KONDO, M. MIZUMOTO, T. KOTAKE, Y. OKITA, T. OGATA, Y. HATACHI, H. YASUI, A. MIKI, Y. IMAI, C. ICHIKAWA, K. MUROTANI, M. KOTAKA, T. KATO, S. KAIHARA, A. TSUJI ( <i>Kobe; Kita; Nagakute; Amagasaki, Japan</i> ).....	3703
Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases. N. OKANO, A. KASUGA, K. KAWAI, T. KOBAYASHI, D. NARUGE, F. NAGASHIMA, J. FURUSE ( <i>Tokyo, Japan</i> ).....	3711
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. B. DETTI, R.M. D'ANGELILLO, G. INGROSSO, E. OLMETTO, G. FRANCOLINI, L. TRIGGIANI, A. BRUNI, S. BORGHESI, S. FONDELLI, T. CARFAGNO, R. SANTINI, R. SANTONI, L.E. TRODELLA, L. LIVI ( <i>Florence; Rome; Brescia; Modena; Arezzo; Siena; Pistoia, Italy</i> ).....	3717
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. G.L. BANNA, H.J.S. PARRA, M. CASTAING, M.V. DIECI, G. ANILE, M. NICOLOSI, S. STRANO, F. MARLETTA, V. GUARNERI, P. CONTE, R. LAL ( <i>Catania; Padua, Italy; London, UK</i> ).....	3723
Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas. P.C. PHUONG, N.D. LUAN, V.T.H. TRANG, S.E. SCHILD, D. RADES, M.T. KHOA ( <i>Hanoi, Vietnam; Scottsdale, AZ, USA; Lübeck, Germany</i> ) .....	3729
Evaluation of a New Technique for iFOBT Utilising a New Sample Collection Device with Increased Buffer Stability. M. BRUNS-TOEPLER, P. HARDT ( <i>Giessen, Germany</i> ).....	3735
Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent. Y. HONMA, N. HOKAMURA, K. NAGASHIMA, K. SUDO, H. SHOJI, S. IWASA, A. TAKASHIMA, K. KATO, T. HAMAGUCHI, N. BOKU, R. UMEZAWA, Y. ITO, J. ITAMI, K. KOYANAGI, H. IGAKI, Y. TACHIMORI ( <i>Tokyo; Chiba, Japan</i> ).....	3741



Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma. S. KRAUTBAUER, T.S. WEISS, R. WIEST, D. SCHACHERER, G. LIEBISCH, C. BUECHLER ( <i>Regensburg, Germany; Bern, Switzerland</i> ) .....	3527
The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients. K. ORYWAL, W. JELSKI, T. WEREL, M. SZMITKOWSKI ( <i>Bialystok, Poland</i> ) .....	3537
The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells. J. PANCEWICZ-WOJTKIEWICZ, P.L. BERNATOWICZ ( <i>Bialystok, Poland</i> ) .....	3543
Correlation Between Thrombospondin-1 Expression in Non-cancer Tissue and Gastric Carcinogenesis. H. KASHIHARA, M. SHIMADA, K. YOSHIKAWA, J. HIGASHIJIMA, T. TOKUNAGA, M. NISHI, C. TAKASU, D. ISHIKAWA ( <i>Tokushima, Japan</i> ) .....	3547
Inhibitory Effects of ATP and Adenosine on Cholangiocarcinoma Cell Proliferation and Motility. J. LERTSUWAN, M. RUCHIRAWAT ( <i>Bangkok, Thailand</i> ) .....	3553
The Contribution of <i>MMP-8</i> Promoter Polymorphisms in Lung Cancer. T.-C. SHEN, T.-C. HSIA, C.-Y. CHAO, WEI-CHENG CHEN, C.-Y. CHEN, WEI-CHUN CHEN, Y.-T. LIN, C.-L. HSIAO, W.-S. CHANG, C.-W. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	3563
A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells. K. SETO, T. SAKABE, N. ITABA, J. AZUMI, H. OKA, M. MORIMOTO, Y. UMEKITA, G. SHIOTA ( <i>Yonago; Koyama, Japan</i> ) .....	3569
Impact of Physical Training on Sex Hormones and Their Receptors During <i>N</i> -Methyl- <i>N</i> -nitrosourea-induced Carcinogenesis in Rats. I. MALICKA, K. SIEWIERSKA, C. KOBIERZYCKI, J. GRZEGRZOLKA, A. PIOTROWSKA, U. PASLAWSKA, M. CEGIELSKI, P. DZIEGIEL, M. PODHORSKA-OKOLOW, M. WOZNIEWSKI ( <i>Wroclaw, Poland</i> ) .....	3581
Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis <i>via</i> Suppression of the Epithelial–Mesenchymal Transition Process. S. PADTHAISONG, M. THANEE, A. TECHASEN, N. NAMWAT, P. YONGVANIT, A. LIWATTHAKUN, K. HANKLA, S. SANGKHAMANON, W. LOILOME ( <i>Khon Kaen, Thailand</i> ) .....	3591
A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. M. NAGASATO, Y. RIN, Y. YAMAMOTO, M. HENMI, N. HIRAOKA, F. CHIWAKI, K. MATSUSAKI, M. TAGAWA, H. SASAKI, K. AOKI ( <i>Tokyo; Chiba, Japan</i> ) .....	3599
Sphingosine-1-Phosphate-Receptor 1 as a Marker for Endothelial Cells in Mouse Xenograft Models of Human Cancer. N. LÜDERS, U. SCHUMACHER ( <i>Hamburg, Germany</i> ) .....	3607
Neocarzinostatin, Aptamer Conjugates for Targeting EpCAM-positive Tumor Cells. P.K. ATHYALA, J.R. KANWAR, S. CHITIPOTHU, R.K. KANWAR, S. KRISHNAKUMAR, J.P. WATSON, J. NARAYANAN ( <i>Chennai, India; Burwood, Australia</i> ) .....	3615
<i>PCA3</i> Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade. E. ÖZGÜR, A.I. CELIK, E. DARENDELILER, U. GEZER ( <i>Istanbul, Turkey</i> ) .....	3631
<i>Clinical Studies</i>	
Slow-release L-Cysteine (Acetium®) Lozenge Is an Effective New Method in Smoking Cessation. A Randomized, Double-blind, Placebo-controlled Intervention. K. SYRJÄNEN, K. ERONEN, P. HENDOLIN, L. PALOHEIMO, C. EKLUND, A. BÄCKSTRÖM, O. SUOVANIEMI ( <i>Helsinki, Finland; Barretos, SP, Brazil</i> ) .....	3639

Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement. C. CHAO, S.G. WIDEN, T.G. WOOD, J.R. ZATARAIN, P. JOHNSON, A. GAJJAR, G. GOMEZ, S. QIU, J. THOMPSON, H. SPRATT, M.R. HELLMICH ( <i>Galveston, TX, USA</i> ) .....	3405
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. K. NATH, D.S. NELSON, J. ROMAN, M.E. PUTT, S.-C. LEE, D.B. LEEPER, J.D. GLICKSON ( <i>Philadelphia, PA, USA</i> ) .....	3413
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine- $\beta$ -Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma. R.E. SHACKELFORD, J. ABDULSATTAR, E.X. WEI, J. COTELINGAM, D. COPPOLA, G.A. HERRERA ( <i>Shreveport, LA; Tampa, FL, USA</i> ).....	3423
Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment. M. NAKAMURA, A. SUETSUGU, K. HASEGAWA, T. MATSUMOTO, H. AOKI, T. KUNISADA, M. SHIMIZU, S. SAJI, H. MORIWAKI, R.M. HOFFMAN ( <i>Gifu, Japan; San Diego, CA, USA</i> ).....	3429
Imaging the Role of Multinucleate Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in Peritoneal Metastasis in Mouse Models. K. HASEGAWA, A. SUETSUGU, M. NAKAMURA, T. MATSUMOTO, H. AOKI, T. KUNISADA, M. SHIMIZU, S. SAJI, H. MORIWAKI, R.M. HOFFMAN ( <i>Gifu, Japan; San Diego, CA, USA</i> ).....	3435
Overexpression of Activin Receptor-like Kinase 7 in Breast Cancer Cells Is Associated with Decreased Cell Growth and Adhesion. T. HU, F. SU, W. JIANG, D.A. DART ( <i>Cardiff, UK; Guangzhou, PR China</i> ) .....	3441
Effects of Pulsed Electromagnetic Fields on Breast Cancer Cell Line MCF 7 Using Absorption Spectroscopy. D.Z. ALCANTARA, I.J.S. SOLIMAN, R.F. POBRE, R.N.G. NAGUIB ( <i>Manila, Philippines; Liverpool, UK</i> ) .....	3453
Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas. S. FURUDATE, T. FUJIMURA, Y. KAMBAYASHI, A. KAKIZAKI, T. HIDAKA, S. AIBA ( <i>Sendai, Japan</i> ) .....	3461
MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. X. FENG, K. MATSUO, T. ZHANG, Y. HU, A.C. MAYS, J.D. BROWNE, X. ZHOU, C.A. SULLIVAN ( <i>Winston-Salem, NC, USA</i> ) .....	3473
Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. G.T. BOLGER, A. LICOLLARI, A. TAN, R. GREIL, B. VCELAR, M. MAJEED, L. HELSON ( <i>Scarborough, Canada; Salzburg; Klosterneuburg, Austria; East Windsor, NJ; Quakertown, PA, USA</i> ) .....	3483
Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells. T. ORFANIDOU, K. XANTHOPOULOS, D. DAFOU, A. PSEFTOGAS, P. HADWEH, C. PSYLLAKI, E. HATZIVASSILIOU, G. MOSIALOS ( <i>Thessaloniki, Greece</i> ).....	3493
Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin–Paclitaxel: A Prospective Study. T. OTSUKA, T. NOJIRI, S. MINAMI, H. HOSODA, M. KUROYAMA, H. HIRATA, K. NAKANISHI, S. YAMAMOTO, K. KOMUTA, K. KANGAWA, T. KIJIMA ( <i>Osaka; Suita; Toyonaka; Itami, Japan</i> ) .....	3505
<i>In Vitro</i> Apoptosis Induction by Fenofibrate in Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, I.G.H. SCHMIDT-WOLF ( <i>Bonn, Germany</i> ) .....	3513
Itraconazole Modulates Hedgehog, WNT/ $\beta$ -catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells. T. UEDA, H. TSUBAMOTO, K. INOUE, K. SAKATA, H. SHIBAHARA, T. SONODA ( <i>Nishinomiya, Japan</i> ) .....	3521